Table 1. Patient characteristics. Overview of the clinico-pathological characteristics of patients (1st column), biopsies (2nd column) and serum samples (3th column).
| Patients n=53(%) | Biopsies n=65 (%) | Serum n=19 (%) | |
|---|---|---|---|
| Gender | |||
| Male | 34 (64%) | 40 (62%) | 16 (84%) |
| Female | 19 (36%) | 25 (38%) | 3 (16%) |
| Histologic Type | |||
| Adenocarcinoma | 36 (68%) | 45 (70%) | 10 (53%) |
| Squamous | 15 (28%) | 18 (28%) | 8 (42%) |
| Large cell | 1 (2%) | 1 (1%) | 1 (5%) |
| Neuro-endocrine | 1 (2%) | 1 (1%) | 0 (5%) |
| Differentiation | |||
| Weak | 13 (25%) | 14 (22%) | 7 (37%) |
| Moderate | 21 (40%) | 24 (37%) | 8 (42%) |
| Strong | 9 (17%) | 10 (15%) | 1 (5%) |
| TxNxMx | |||
| T1 | 10 (19%) | 11 (17%) | 3 (16%) |
| T2 | 18 (34%) | 19 (29%) | 8 (42%) |
| T3 | 15 (28%) | 15 (23%) | 7 (37%) |
| T4 | 5 (9%) | 5 (8%) | 1 (5%) |
| Relapse | |||
| Lung | 4 (8%) | 2 (3%) | 0 (0%) |
| Metastasis | |||
| Lymph node | 20 (34%) | 8 (12%) | 6 (32%) |
| Organ | 8 (15%) | 2 (3%) | 0 (0%) |
| Genetic aberrations | |||
| EGFR mutation | 12 (23%) | 15 (23%) | 2 (11%) |
| Alk translocation | 3 (6%) | 3 (5%) | 0 (0%) |